Company News
Galectin Therapeutics Shares Jump 20% After FDA Agreement
Galectin Therapeutics' stock rose about 20% after FDA agreed on primary endpoint and regulatory path for belapectin's Phase 3 trial.
The FDA accepted a composite liver outcome, including prevention of
